Amarin Corporation

AMRNPhase 2

Amarin Corporation is a global biopharmaceutical company with a mission to improve cardiovascular health through innovative science. Its primary achievement is the development and commercialization of VASCEPA® (icosapent ethyl), a drug with a landmark cardiovascular outcomes trial (REDUCE-IT) that demonstrated significant risk reduction in major adverse cardiovascular events. The company's strategic direction involves defending and expanding the market for VASCEPA, while also exploring its potential in other indications and advancing its pipeline. Amarin faces the challenge of navigating generic competition and payer reimbursement dynamics while seeking to maximize the global value of its core asset.

Market Cap

$3.6B

Employees

300-500

Focus

Biotech

AMRN · Stock Price

USD 174.40+160.80 (+1182.35%)

Historical price data

AI Company Overview

Technology Platform

Clinical development and lifecycle management expertise for a specific, high-purity prescription omega-3 fatty acid (icosapent ethyl), with a deep understanding of its multifactorial mechanisms in cardiovascular risk reduction.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage	Watch
Icosapent ethyl	Covid19	Approved
Icosapent ethyl	COVID-19	Phase 2

Funding History

Total raised: $362M

PIPE$200MBaker Bros. AdvisorsMay 15, 2020

Debt$100MPharmakon AdvisorsDec 15, 2019

IPO$62MUndisclosedJan 1, 1993

Opportunities

Significant opportunity lies in expanding the global footprint of VASCEPA/VAZKEPA, particularly in Europe and potentially China following trial completion.

Growth can be driven by increased guideline inclusion, physician education on the unique outcomes data, and successful market access negotiations.

Further lifecycle management through new indications or formulations represents additional long-term potential.

Risk Factors

The company faces extreme concentration risk from reliance on a single product.

The greatest immediate risk is the ongoing erosion of U.S.

revenue due to generic competition.

Additional risks include slower-than-expected adoption in international markets, unfavorable payer reimbursement decisions, and failure to successfully defend remaining intellectual property or regulatory exclusivity.

Competitive Landscape

Amarin's main competitors are generic manufacturers of icosapent ethyl in the U.S. and other lipid-modifying and cardiovascular risk reduction therapies globally (e.g., PCSK9 inhibitors, fibrates, bempedoic acid). Its key differentiation is the strong cardiovascular outcomes data from the REDUCE-IT trial, which is not matched by other omega-3 products. However, this differentiation is challenged by the price advantage of generics.